Quick Summary: Apollo Hospitals will acquire IFC’s 31% stake in Apollo Health & Lifestyle for ₹1,254 crore, making it a nearly wholly-owned subsidiary. Alongside, the group announced a ₹573 crore investment to set up a 100-bed Comprehensive Oncology Centre in Gurugram equipped with advanced Proton Therapy, strengthening its leadership in cancer care.
Full Article: Apollo Hospitals Enterprise Ltd (AHEL) has announced major strategic moves, including acquiring International Finance Corporation’s (IFC) stake in Apollo Health and Lifestyle Ltd (AHLL) and setting up a new oncology facility in Gurugram.
The board has approved the purchase of 4.16 crore equity shares, representing a 30.58% stake jointly held by IFC and IFC EAF Apollo Investment Company in AHLL, for a total consideration of ₹1,254.07 crore. Once completed, AHLL will become a 99.42% subsidiary of AHEL, with the balance 0.58% held under an ESOP pool. The transaction, subject to approval by the Competition Commission of India, is expected to close by November 2025.
AHLL, incorporated in 2000, operates specialty hospitals, clinics, diagnostic centres, birthing centres, dental and dialysis facilities across India. For the financial year ending March 2025, the company reported a consolidated turnover of ₹1,553.5 crore.
Separately, Apollo Hospitals announced plans to set up a 100-bed Comprehensive Oncology Centre in Gurugram with a next-generation Proton Therapy system. The project, part of the Phase 2 expansion of its upcoming 500-bed hospital in the city, involves an investment of ₹573 crore, funded through internal accruals. The centre is targeted for completion by FY 2029.
With this expansion, Apollo will strengthen its nationwide oncology program, building on its existing proton therapy facilities in Chennai and Hyderabad. The Gurugram centre will provide advanced cancer care, including precision medicine, robotics, immunotherapy, and genomics-driven treatments.
Company officials noted that these initiatives are aimed at consolidating ownership, improving operational efficiency, and scaling Apollo’s oncology business across India’s metropolitan markets.